ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد ایتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Trichloroacetic acid: Drug information

Trichloroacetic acid: Drug information
(For additional information see "Trichloroacetic acid: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Tri-Chlor [DSC]
Pharmacologic Category
  • Keratolytic Agent
Dosing: Adult

Condylomata: Topical: Applied by a health care provider and allowed to dry to white frost on tissue before patient sits or stands. Therapy may be repeated weekly if necessary (CDC [Workowski 2021]).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Liquid, External:

Tri-Chlor: 80% (15 mL [DSC])

Generic Equivalent Available: US

No

Administration: Adult

Topical: Solution has a low viscosity of solution similar to water. Health care provider should use caution to avoid applying excessive amounts or exposing surrounding tissue to solution. For intense pain following application or excessive tissue exposure, sodium bicarbonate (ie, baking soda), liquid soap, or talc may be effective neutralizers or help remove unreacted acid (CDC [Workowski 2021]).

Use: Labeled Indications

Condylomata: To aid in the elimination of condylomata (external anogenital warts).

Limitations of use: The Centers for Disease Control and Prevention sexually transmitted infections guidelines recommend trichloroacetic acid as a health care provider-administered option for the treatment of external anogenital warts (eg, penis, groin, vulva, perineum, external anus, and perianus). Although trichloroacetic acid has been widely used for this, it has not been thoroughly investigated (CDC [Workowski 2021]).

Adverse Reactions

There are no adverse reactions listed in the manufacturer's labeling.

Warnings/Precautions

Other warnings/precautions:

• Appropriate use: For prescription compounding and application by physician as part of a procedure. Serious injuries, including skin damage, burns, swelling, and pain may occur following improper application.

Metabolism/Transport Effects

None known.

Drug Interactions

There are no known significant interactions.

Pregnancy Considerations

Effective when used topically for the treatment of genital condylomas in pregnant patients (Schwartz 1988). However, other agents may be preferred for use (CDC [Workowski 2021]).

Pricing: US

Liquid (Tri-Chlor External)

80% (per mL): $5.17

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Acido Tricloroacetico (IT);
  • CL3 Bruciaporri (IT)


For country abbreviations used in Lexicomp (show table)
  1. Schwartz DB, Greenberg MD, Daoud Y, et al. Genital condylomas in pregnancy: use of trichloroacetic acid and laser therapy. Am J Obstet Gynecol. 1988;158(6, pt 1):1407-1416. [PubMed 3381865]
  2. Tri-Chlor (trichloroacetic acid) [prescribing information]. Upper Darby, PA: Gordon Laboratories; July 2010.
  3. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1 [PubMed 34292926]
Topic 10296 Version 80.0